More Heart, Less Skin: US FDA’s 2025 Novel Approvals Should Reflect Pipeline Shifts

 
• By Bridget Silverman
  
The US FDA is looking at a shifting landscape of potential novel agents in the class of 2025. (Shutterstock)

More from Pink Sheet Perspectives

More from Geography